GlassScriptPhysician profile
Kevin K Snyder
NPI 1013946706
$2,660.04
in general payments reported to CMS, 2019-2025
23 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $456 · 2021: $494 · 2022: $424 · 2023: $349 · 2024: $283 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $933.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $456.52 | 2019-2025 | Sublocade, Perseris |
| Abbvie INC. | $394.74 | 2021-2024 | Vraylar |
| Alkermes, INC. | $264.10 | 2019-2025 | Aristada, Vivitrol, Lybalvi |
| Sunovion Pharmaceuticals INC. | $216.46 | 2019-2022 | |
| Allergan, INC. | $178.64 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $171.11 | 2019-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $149.30 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $119.06 | 2019-2023 | Ingrezza |
| Uswm, LLC | $115.74 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $113.72 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $75.37 | 2020-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $68.91 | 2019-2023 | Rexulti |
| Neuronetics, INC. | $59.16 | 2024 | Neurostar Tms Therapy System |
| Eisai INC. | $47.45 | 2020-2022 | |
| Tempus Ai, INC | $43.91 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $37.79 | 2022 | |
| Braeburn INC. | $28.12 | 2025 | Brixadi |
| Mdd US Operations, LLC | $25.92 | 2019-2020 | |
| Orexo US, INC. | $23.81 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.33 | 2023 | |
| Shire North American Group INC | $18.35 | 2019 | |
| Noven Therapeutics, LLC | $17.81 | 2021 | |
| Acadia Pharmaceuticals INC | $13.72 | 2023 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Snyder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.